Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

W. K. Goodman, L. H. Price, S. A. Rasmussen, P. L. Delgado, G. R. Heninger, D. S. Charney

Research output: Contribution to journalArticle

346 Citations (Scopus)

Abstract

A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder (OCD). Approximately one half of the patients also had symptoms of major depression. Fluvoxamine was significantly better than placebo on all measures of obsessive-compulsive symptoms. Nine of 21 patients were responders ('much improved') with fluvoxamine compared with no responders with placebo, and fluvoxamine was effective in patients with OCD both with and without secondary depression. Response of OCD was not correlated with severity or baseline depression. These data lend partial support to the serotonin hypothesis of OCD. However, since a number of patients failed to respond to fluvoxamine, the role of other neurochemical systems in this disorder needs to be explored.

Original languageEnglish (US)
Pages (from-to)36-44
Number of pages9
JournalArchives of General Psychiatry
Volume46
Issue number1
StatePublished - 1989
Externally publishedYes

Fingerprint

Fluvoxamine
Obsessive-Compulsive Disorder
Placebos
Depression
Serotonin Uptake Inhibitors
Serotonin

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Goodman, W. K., Price, L. H., Rasmussen, S. A., Delgado, P. L., Heninger, G. R., & Charney, D. S. (1989). Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Archives of General Psychiatry, 46(1), 36-44.

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. / Goodman, W. K.; Price, L. H.; Rasmussen, S. A.; Delgado, P. L.; Heninger, G. R.; Charney, D. S.

In: Archives of General Psychiatry, Vol. 46, No. 1, 1989, p. 36-44.

Research output: Contribution to journalArticle

Goodman, WK, Price, LH, Rasmussen, SA, Delgado, PL, Heninger, GR & Charney, DS 1989, 'Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo', Archives of General Psychiatry, vol. 46, no. 1, pp. 36-44.
Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Archives of General Psychiatry. 1989;46(1):36-44.
Goodman, W. K. ; Price, L. H. ; Rasmussen, S. A. ; Delgado, P. L. ; Heninger, G. R. ; Charney, D. S. / Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. In: Archives of General Psychiatry. 1989 ; Vol. 46, No. 1. pp. 36-44.
@article{47a223642119404fb62bd4445af87207,
title = "Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo",
abstract = "A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder (OCD). Approximately one half of the patients also had symptoms of major depression. Fluvoxamine was significantly better than placebo on all measures of obsessive-compulsive symptoms. Nine of 21 patients were responders ('much improved') with fluvoxamine compared with no responders with placebo, and fluvoxamine was effective in patients with OCD both with and without secondary depression. Response of OCD was not correlated with severity or baseline depression. These data lend partial support to the serotonin hypothesis of OCD. However, since a number of patients failed to respond to fluvoxamine, the role of other neurochemical systems in this disorder needs to be explored.",
author = "Goodman, {W. K.} and Price, {L. H.} and Rasmussen, {S. A.} and Delgado, {P. L.} and Heninger, {G. R.} and Charney, {D. S.}",
year = "1989",
language = "English (US)",
volume = "46",
pages = "36--44",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

AU - Goodman, W. K.

AU - Price, L. H.

AU - Rasmussen, S. A.

AU - Delgado, P. L.

AU - Heninger, G. R.

AU - Charney, D. S.

PY - 1989

Y1 - 1989

N2 - A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder (OCD). Approximately one half of the patients also had symptoms of major depression. Fluvoxamine was significantly better than placebo on all measures of obsessive-compulsive symptoms. Nine of 21 patients were responders ('much improved') with fluvoxamine compared with no responders with placebo, and fluvoxamine was effective in patients with OCD both with and without secondary depression. Response of OCD was not correlated with severity or baseline depression. These data lend partial support to the serotonin hypothesis of OCD. However, since a number of patients failed to respond to fluvoxamine, the role of other neurochemical systems in this disorder needs to be explored.

AB - A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder (OCD). Approximately one half of the patients also had symptoms of major depression. Fluvoxamine was significantly better than placebo on all measures of obsessive-compulsive symptoms. Nine of 21 patients were responders ('much improved') with fluvoxamine compared with no responders with placebo, and fluvoxamine was effective in patients with OCD both with and without secondary depression. Response of OCD was not correlated with severity or baseline depression. These data lend partial support to the serotonin hypothesis of OCD. However, since a number of patients failed to respond to fluvoxamine, the role of other neurochemical systems in this disorder needs to be explored.

UR - http://www.scopus.com/inward/record.url?scp=0024495403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024495403&partnerID=8YFLogxK

M3 - Article

C2 - 2491940

AN - SCOPUS:0024495403

VL - 46

SP - 36

EP - 44

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 1

ER -